Grey Bradshaw-Mack

We find the best experts in every professional domain and put their knowledge to work training frontier models. Through APEX, we measure whether those models can actually perform economically valuable work. Were also bringing that expertise to enterprises: deploying custom AI agents, staffing teams with vetted domain experts, and helping organizations encode their own knowledge into AI systems.

We find the best experts in every professional domain and put their knowledge to work training frontier models. Through APEX, we measure whether those models can actually perform economically valuable work. Were also bringing that expertise to enterprises: deploying custom AI agents, staffing teams with vetted domain experts, and helping organizations encode their own knowledge into AI systems.

PitchBook is the leading resource for comprehensive data, research and insights spanning the global capital markets. Our unprecedented offerings are brought to life through the PitchBook Platform, a dynamic suite of products designed to help you win. Founded in 2007, CEO John Gabbert knew that his idea for an actionable, extensive database for private equity-focused intelligence was worth pursuing. The rest is PitchBook history. Since those early days, PitchBook has expanded its coverage areas to include the entirety of the global public and private markets. We’ve added thousands of datasets and millions of individual insights into the platform, and we’ve pioneered new features and products that surface the information our clients need. We look at every day as a new opportunity to meet and exceed our customers’ expectations through helping them make informed decisions that propel their firms forward. Now part of Morningstar, PitchBook is headquartered in Seattle, London, and Singapore with additional offices in New York and San Francisco.

The Michael J. Fox Foundation for Parkinsons Research is dedicated to finding a cure for Parkinsons disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinsons today.